Radical nephrectomy with venous tumor thrombus excision up to level III in RCC patients yielded median progression-free, cancer-specific, and overall survival of 23, 60, and 48 months, respectively.
Cohort (n=64)
No
What are the survival outcomes and predictors of cancer-specific survival in patients undergoing radical nephrectomy with VTT excision up to level III for renal cell carcinoma?
Radical nephrectomy with VTT excision up to level III is a feasible and safe procedure for RCC, with specific tumor characteristics predicting worse cancer-specific survival.
Background: The purpose of this study is to report the experience of a single Portuguese oncology center in the management of patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT). Methods: This is a retrospective analysis of all patients with RCC and VTT surgically treated in our center between 2008 and 2023. Only patients with VTT up to level III (Mayo Clinic classification) were included. Patient, tumor characteristics and peri-operative outcome data were registered. Administration of systemic therapy was performed upon progression. Survival analysis was conducted with the collected data. Results: A total of 64 patients (n = 16 women) were included in this study. The mean age at diagnosis was 66.3 ± 10.7 years old. The VTT level was 0, I, II and III in 40 (62.5%), 12 (18.7%), 6 (9.4%) and 6 (9.4%) patients, respectively. Nine patients (14.1%) had distant metastasis at diagnosis. No peri-operative deaths occurred, and the major complication rate was 3.1%. Histology revealed 98.4% of clear cell RCC, with sarcomatoid differentiation present in 12.5% of the cases. A negative margin status was achieved in 54 (84.4%) patients. Systemic therapy was administered in 24 (37.5%) patients during follow-up. The median progression-free (PFS), cancer-specific (CSS) and overall (OS) survival were 23, 60 and 48 months, respectively. In multivariable analysis, significant predictors of CSS were tumor size, sarcomatoid differentiation and collecting system invasion. Conclusions: Radical nephrectomy with VTT excision up to level III is a feasible and safe procedure. Patients with large tumor size, sarcomatoid differentiation and collecting system invasion are at the highest risk and should be closely monitored.
Faria‐Costa et al. (Sun,) conducted a cohort in Renal cell carcinoma (RCC) with venous tumor thrombus (VTT) (n=64). Radical nephrectomy with VTT excision was evaluated on Progression-free (PFS), cancer-specific (CSS) and overall (OS) survival. Radical nephrectomy with venous tumor thrombus excision up to level III in RCC patients yielded median progression-free, cancer-specific, and overall survival of 23, 60, and 48 months, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: